These data together show that IgA-EpCAM antibodies can kill PDAC patient tumor cells ex vivo, emphasizing the rationale to continue testing IgA therapy, in combination with CD47 blockade, for treatment of PDAC. This evidence concerns the gene EPCAM and neoplasm.